Clinical trials: Alopecia Areata(AA)
Alopecia Areata(AA)
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata
This study includes a dose escalation part(phase I) and a dose extension part(phase II).
- Trial name
- AA (NCT04445363)
- Testing
- Jaktinib hydrochloride cream
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Alopecia Areata
Regeneron AA Multicenter (Dupilumab)
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the…
- Trial name
- NCT05551793
- Testing
- Dupilumab
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Emma Guttman
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Totalis/Universalis, Alopecia Areata(AA)
Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
The goal of this observational study is to evaluate safety of Rhofanib® (Tofacitinib) in male or female participants with the age of 18 years or older having clinical diagnosis of Alopecia.
- Trial name
- NCT07101471
- Testing
- Tofacitinib
- Where
- Iran
- Volunteers
- 296 people
- Sponsor
- NanoAlvand
Alopecia Areata, Alopecia Areata(AA)
Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata
The goal of this observational study is to learn about microvascular changes and hair follicle activity in patients with alopecia areata.
- Conditions
- Alopecia Areata, Alopecia Areata(AA), Alopecia Areata (AA)
- Trial name
- NCT07499713
- Testing
- Microvascular Imaging, Biochemical Biomarker Analysis, Trichoscopic Imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Istanbul Training and Research Hospital
Alopecia Areata
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia areata (AA) is a chronic relapsing autoimmune disease characterized by nonscarring hair loss affecting children, adolescents, and adults across all ages, races, and genders.
- Trial name
- PRESTO (NCT06531109)
- Testing
- Ritlecitinib
- Where
- 70 sites in United States, China and 4 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Alopecia Areata, Alopecia Totalis (AT)
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair) and alopecia universalis (loss of scalp and body hair).
- Conditions
- Alopecia Areata, Alopecia Totalis (AT), Alopecia Universalis
- Trial name
- TOFA-MTX-AA (NCT07406204)
- Testing
- Tofacitinib, Methotrexate
- Volunteers
- 78 people
- Sponsor
- Hayat Abad Medical Complex, Peshawar
Alopecia Areata, Alopecia Areata(AA)
To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata
Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss, ranging from minor patches to complete baldness.
- Trial name
- NCT06786689
- Testing
- Azathioprine (AZA), Betamethasone
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Sheikh Zayed Medical College
Alopecia Areata, Vitiligo
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
- Trial name
- NCT06602232
- Testing
- DR-01
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 81 people
- Sponsor
- Dren Bio
Alopecia Areata(AA)
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
- Trial name
- IL-2 (NCT07049328)
- Testing
- HCW9302, an IL-2 fusion protein
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- HCW Biologics
Alopecia Areata
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper…
- Trial name
- NCT05745389
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- CorEvitas
Alopecia Areata
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body.
- Trial name
- NCT03359356
- Testing
- Dupilumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alopecia Areata, Janus Kinase Inhibitors
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing.
- Trial name
- NCT06573593
- Testing
- Tofacitinib, Baricitinib, Ruxolitinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Alopecia Areata(AA)
Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata
Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response.
- Trial name
- NR3C1 and AA (NCT07455708)
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Benha University
Alopecia Areata
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers.
- Trial name
- NCT06562270
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorEvitas
Alopecia Areata
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
Alopecia areata (AA) is a common disease of the immune system, known as an "autoimmune" disease. In this disease, the immune system mistakenly destroys the hair follicle, causing hair to fall out.
- Trial name
- NCT02018042
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Alopecia Areata
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with…
- Trial name
- NCT06340360
- Testing
- Rezpegaldesleukin
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 94 people
- Sponsor
- Nektar Therapeutics
Alopecia Areata(AA), Alopecia Areata
Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata
This study aims to investigate the potential role of the ferroptosis pathway in the pathogenesis and clinical course of Alopecia Areata (AA).
- Conditions
- Alopecia Areata(AA), Alopecia Areata, Alopecia Areata (& Ophiasis), Alopecia
- Trial name
- NCT07733063
- Where
- Turkey (Türkiye)
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Istanbul Training and Research Hospital
Alopecia Areata
A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
A Phase 2 double-blind, multi-site, placebo-controlled, parallel-group design to assess the efficacy, safety and dose-response characterisation of STS-01 for the treatment of mild- moderate alopecia areata.
- Trial name
- SOT01 (NCT06402630)
- Testing
- STS01
- Where
- 9 sites in United Kingdom
- Volunteers
- 158 people
- Sponsor
- Soterios Ltd
Alopecia Areata
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
The purpose of the study is to evaluate the pharmacokinetics (how the medicine is changed and eliminated from your body after you take it) and pharmacodynamics (effects of the medicine in the body) of the study medicine (called…
- Trial name
- NCT05650333
- Testing
- Ritlecitinib 20 mg
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer